Neural Stem Cells Market Size
The global neural stem cells market size reached US$ 4.21 Billion in 2024 and is expected to reach US$ 7.25 Billion by 2033, growing at a CAGR of 6.3% during the forecast period 2025-2033.
Neural Stem Cells Market Overview
The global neural stem cells market is experiencing robust growth, driven by the increasing prevalence of neurological disorders, technological advancements in regenerative medicine, and expanding research applications. Neural stem cells are multipotent cells capable of self-renewal and differentiation into neurons, astrocytes, and oligodendrocytes, making them highly valuable for both therapeutic interventions and in vitro disease modeling. Their unique capacity to regenerate central nervous system (CNS) tissue places NSCs at the forefront of potential treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, spinal cord injury, and multiple sclerosis.
Neural Stem Cells Market Executive Summary

Neural Stem Cells Market Dynamics: Drivers & Restraints
The rising prevalence of neurological disorders is significantly driving the neural stem cells market growth
The rising prevalence of neurological disorders is a major growth driver for the neural stem cells (NSCs) market because these disorders represent a significant unmet medical need with limited effective treatments. NSCs offer promising regenerative and reparative potential for conditions where damaged neurons cannot naturally regenerate. According to the Alzheimer's Association, around 7 million people in the U.S. currently live with Alzheimer’s, projected to nearly double to 13 million by 2050. Existing therapies mostly manage symptoms without halting progression. NSCs have the potential to replace lost neurons and restore cognitive functions, creating strong demand for NSC-based therapies.
A Parkinson’s Foundation-backed study revealed that nearly 90,000 people are diagnosed with Parkinson’s disease in the U.S. each year. This represents a steep 50% increase from the previously estimated rate of 60,000 diagnoses annually. NSC therapies aim to replenish dopaminergic neurons lost in Parkinson’s, providing a disease-modifying approach that current treatments lack. The first autologous NSC trial (Aspen Neuroscience’s ASPIRO) began dosing in 2024, reflecting clinical momentum.
The high cost associated with neural stem cell products is hampering the growth of the market
The process of isolating, culturing, and expanding neural stem cells is complex and requires high levels of precision. Producing high-quality neural stem cells involves expensive bioreactors, specific growth factors, and strict sterile conditions. The need for sophisticated equipment, such as automated stem cell culturing systems, increases costs. For instance, iXCells Biotechnologies’ human neural stem cells (iPSC-derived, ALS) cost $1,078.00, and STEMCELL Technologies’ human IPSC-derived neural progenitor cells cost $995.00.
For more details on this report – Request for Sample
Neural Stem Cells Market, Segment Analysis
The global neural stem cells market is segmented based on type, application, end-user, and region.
Parkinson's disease from the application segment is expected to hold 22.31% of the market share in 2024 in the neural stem cells market
The National Institute of Health has estimated that the number of people with Parkinson's disease over the age of 50 years is expected to reach around 9 million by 2030, a doubling since 2005, rising to over 12 million by 2040. Parkinson’s disease, a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain, affects millions of people globally. The demand for innovative therapies, particularly stem cell-based treatments, has driven the substantial focus on Parkinson’s disease within the neural stem cells market.
Current Parkinson's disease therapies, such as levodopa, dopamine agonists, only manage symptoms and lose efficacy over time, often leading to dyskinesias and other side effects. Neural stem cells offer the promise of replacing lost dopaminergic neurons or delivering trophic support to slow disease progression capabilities that pharmacologics cannot match.
Neural Stem Cells Market, Geographical Analysis
North America is expected to dominate the global neural stem cells market with a 43.02% share in 2024
For instance, in April 2024, Aspen Neuroscience, Inc. said that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open-label clinical trial to assess the safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate to severe Parkinson's disease (PD).
Asia-Pacific is growing at the fastest pace in the neural stem cells market, holding 21.08% of the market share
Countries like China, Japan, and South Korea have implemented favorable policies and regulations to promote stem cell research and therapy. For instance, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has expedited the approval process for regenerative medicines, while China has established the National Medical Products Administration (NMPA) to streamline regulatory pathways.
The region is witnessing significant advancements in stem cell technologies, including the development of induced pluripotent stem cells (iPSCs) and 3D bioprinting. In 2023, Japan recorded 35 newly launched clinical collaborations for iPSC-driven treatments, reflecting a strong commitment to personalized and off-the-shelf regenerative solutions.
Neural Stem Cells Market Competitive Landscape
Top companies in the neural stem cells market include Athersys, Inc., Thermo Fisher Scientific Inc., STEMCELL Technologies, Merck KGaA, Axol Bioscience Ltd., iXCells Biotechnologies, ALSTEM, Bio-Rad Laboratories, Inc., Alomone Labs, and Lifeline Cell Technology, among others.
Neural Stem Cells Market Scope
Metrics | Details | |
CAGR | 6.3% | |
Market Size Available for Years | 2022-2033 | |
Estimation Forecast Period | 2025-2033 | |
Revenue Units | Value (US$ Bn) | |
Segments Covered | Type | Human Neural Stem Cells, Animal-Derived Neural Stem Cells, Embryonic Stem Cells, Induced Pluripotent Stem Cells |
Application | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Traumatic Brain Injury, Schizophrenia, Epilepsy, Others | |
End-User | Hospitals and Clinics, Research Institutions and Academic Centers, Pharmaceutical and Biotech Companies, Others | |
Regions Covered | North America, Europe, Asia-Pacific, South America, and the Middle East & Africa |
The global neural stem cells market report delivers a detailed analysis with 70 key tables, more than 78 visually impactful figures, and 185 pages of expert insights, providing a complete view of the market landscape.